Allergy Therapeutics plc (AIM:AGY)
London flag London · Delayed Price · Currency is GBP · Price in GBX
11.50
-0.89 (-7.72%)
Mar 9, 2026, 4:35 PM GMT

Allergy Therapeutics Ratios and Metrics

Millions GBP. Fiscal year is Jul - Jun.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 2020 - 2016
Market Capitalization
7283792507134160
Upgrade
Market Cap Growth
128.04%51.72%3402.67%-94.66%-16.71%80.14%
Upgrade
Enterprise Value
7764022462102124
Upgrade
Last Close Price
0.120.080.050.000.100.12
Upgrade
PE Ratio
-----55.59
Upgrade
PS Ratio
13.236.884.530.121.841.90
Upgrade
PB Ratio
-25.83-13.4433.953.453.543.31
Upgrade
P/TBV Ratio
--93.58-4.083.67
Upgrade
P/FCF Ratio
-----26.62
Upgrade
P/OCF Ratio
-----18.68
Upgrade
PEG Ratio
-5.655.655.655.655.65
Upgrade
EV/Sales Ratio
14.097.304.460.031.401.47
Upgrade
EV/EBITDA Ratio
-----20.31
Upgrade
EV/EBIT Ratio
-----31.62
Upgrade
EV/FCF Ratio
-24.72----20.60
Upgrade
Debt / Equity Ratio
-2.13-2.134.2117.420.280.23
Upgrade
Debt / EBITDA Ratio
-----1.44
Upgrade
Debt / FCF Ratio
-----1.85
Upgrade
Net Debt / Equity Ratio
-1.68-1.682.4610.23-0.26-0.60
Upgrade
Net Debt / EBITDA Ratio
-1.81-1.81-0.56-0.640.98-4.76
Upgrade
Net Debt / FCF Ratio
-1.51-1.51-0.51-0.630.59-4.83
Upgrade
Asset Turnover
0.820.820.830.850.900.97
Upgrade
Inventory Turnover
1.931.932.092.292.092.11
Upgrade
Quick Ratio
0.690.691.021.071.462.46
Upgrade
Current Ratio
1.271.271.781.812.353.17
Upgrade
Return on Equity (ROE)
---819.81%-216.27%-31.93%6.25%
Upgrade
Return on Assets (ROA)
-26.58%-26.58%-32.23%-31.48%-9.60%2.81%
Upgrade
Return on Invested Capital (ROIC)
-149.09%-127.92%-141.18%-138.02%-52.41%16.12%
Upgrade
Return on Capital Employed (ROCE)
-70.60%-70.60%-72.10%-73.00%-22.50%5.60%
Upgrade
Earnings Yield
-5.51%-10.59%-15.46%-604.03%-10.31%1.80%
Upgrade
FCF Yield
-4.31%-8.28%-14.23%-470.51%-12.76%3.76%
Upgrade
Buyback Yield / Dilution
-27.33%-27.33%-458.41%-4.26%4.98%-0.47%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.